News & Events

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Executive Severance and Change in Control Plan and Hider Offer Letter Amendment On May 4, 2026, the Compensation and Human Capital Committee of the Board of Directors (the “Board”) of Baxter International Inc. (the “Company”) approved the Baxter International Inc. Executive Severance and Change in Control Plan (the “Severance Plan”), effective as o…

of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

Other Events. Effective April 29, 2026, the Company's Board of Directors declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on July 1, 2026, to stockholders of record as of May 29, 2026.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Transition of Joel Grade as CFO; Appointment of Anita Zielinski as Interim CFO On March 16, 2026, Baxter International Inc. (the “Company”) announced that, as of such date (the “Transition Date”), Joel Grade’s service as Executive Vice President and Chief Financial Officer (“CFO”) of the Company has ceased and, as of such date, Mr. Grade has transi…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Michael R. McDonnell On February 10, 2026, Baxter International Inc. (the “Company”) appointed Michael R. McDonnell to its Board of Directors (the “Board”), effective February 13, 2026. Mr. McDonnell has also been appointed to serve as a member of the Audit Committee. Michael McDonnell served as the Executive Vice President and Chief…

Other Events Effective February 11, 2026, the Company's Board of Directors declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on April 1, 2026, to stockholders of record as of February 27, 2026.

of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

Other Events. Final Results of Tender Offers On December 22, 2025 (the “Final Settlement Date”), Baxter International Inc. (the “Company”) effected the final settlement of the Company’s previously announced cash tender offers (each, a “Tender Offer” and together, the “Tender Offers”) to purchase (i) any and all of its 2.600% senior unsecured notes due 2026 (the “2026 Notes”) and (ii) a portion of its 1.915% senior unsecured notes due 2027 in an aggregate purchase price up to $600 million (the…

Termination of a Material Definitive Agreement. On December 4, 2025, the Company repaid all of its outstanding obligations under the Term Loan Credit Agreement using a portion of the net proceeds from the Notes.

below) ((i)-(iv), together with the offering of the Notes, the “Refinancing Transactions”). The Company intends to use any remaining net proceeds for general corporate purposes, including the payment of any fees and expenses in connection with the Refinancing Transactions and the November 25, 2025 amendment to its amended and restated five-year credit agreement dated June 11, 2025 and the repayment of the Company’s other indebtedness. Interest Rate and Maturity Interest on the 2029 Notes will…

Entry into a Material Definitive Agreement. Notes Offerings General On December 4, 2025, Baxter International Inc. (the “Company”) entered into the First Supplemental Indenture (the “Supplemental Indenture”) with U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), which supplements the Indenture, dated July 29, 2021 (the “Base Indenture” and together with the Supplemental Indenture, the “Indenture”), between the Company and the Trustee, relating to the issuance by the C…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information included in

Entry into a Material Definitive Agreement. On November 25, 2025, Baxter International Inc. (“ Baxter ”) entered into an amendment (“ Amendment No. 1 ”) to the amended and restated five-year credit agreement dated June 11, 2025, among Baxter, as Borrower Representative, Baxter Healthcare SA and Baxter World Trade SRL, as Borrowers, various lenders and JPMorgan Chase Bank, N.A., as Administrative Agent (as amended by Amendment No. 1, the “ Amended Credit Agreement ”). The purpose of Amendment…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 5, 2025, Alok Sonig notified Baxter International Inc. (the “Company”) of his decision to resign as the Company’s Executive Vice President and Group President, Pharmaceuticals, effective as of December 1, 2025, to join a company in the healthcare industry. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, th…

of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 16, 2025, Heather Knight notified Baxter International Inc. (the “Company”) of her decision to resign as the Company’s Executive Vice President, Chief Operating Officer (“COO”) and interim group president of Medical Products and Therapies (“MPT”), effective as of October 29, 2025 (the “Transition Date”), to join a company in the healthca…

of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Andrew Hider as President and Chief Executive Officer and Director; Transition of Brent Shafer from Interim CEO and Chair to Non-Executive Chair of the Board On July 7, 2025 (the “Announcement Date”), Baxter International Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) has appointed Andrew Hide…

Entry into a Material Definitive Agreement. U.S. $2,200,000,000 Amended and Restated Five-Year Credit Agreement On June 11, 2025, Baxter International Inc. (“ Baxter ”) entered into an amended and restated five-year credit agreement (the “ RCF Amendment ”), which amends and restates in its entirety the existing $2.0 billion revolving credit agreement, dated as of September 30, 2021 (the “ Existing Revolving Credit Agreement ” and, as amended by the RCF Amendment, the “ Revolving Credit Agreem…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure provided under “Credit Agreements” in

Termination of a Material Definitive Agreement The disclosure provided under “Credit Agreements” in

of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Transition of José Almeida as CEO and Chair; Appointment of Brent Shafer as Interim CEO and Chair On February 3, 2025, the Company announced that, effective as of February 3, 2025 (the “CEO Transition Date”), José E. Almeida’s service as Chief Executive Officer (“CEO”) of the Company, Chair of the Board of Directors (the “Board”) and director has c…

and Item 7.01, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except in the event that the Company expressly states that such information is…